Cargando…

Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin — Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes

The last decade has witnessed the role of dipeptidyl peptidase-4 (DPP-4) inhibitors in producing a conceptual change in early management of type 2 diabetes mellitus (T2DM) by shifting emphasis from a gluco-centric approach to holistically treating underlying pathophysiological processes. DPP-4 inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strain, William David, Paldánius, Päivi M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Touch Medical Media 2017
Materias:	Type 2 Diabetes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813466/ https://www.ncbi.nlm.nih.gov/pubmed/29632609 http://dx.doi.org/10.17925/EE.2017.13.02.62

Ejemplares similares

Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance
por: Mathieu, Chantal, et al.
Publicado: (2017)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration
por: Foley, James E, et al.
Publicado: (2017)

Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2017)

Substitution among milk and yogurt products and the risk of incident type 2 diabetes in the EPIC‐NL cohort
por: Stuber, J. M., et al.
Publicado: (2020)

Effects of potato resistant starch intake on insulin sensitivity, related metabolic markers and appetite ratings in men and women at risk for type 2 diabetes: a pilot cross‐over randomised controlled trial
por: Sanders, L. M., et al.
Publicado: (2020)

Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
por: Anno, Takatoshi, et al.
Publicado: (2018)

Beta-cell Insufficiency
por: Kalra, Sanjay, et al.
Publicado: (2017)

Vildagliptin, a dipeptidyl peptidase-4 inhibitor, attenuated endothelial dysfunction through miRNAs in diabetic rats
por: Zhang, Qian, et al.
Publicado: (2019)

Functional Dipeptidyl Peptidase 4 (DPP4) in mink supports entry and replication of Middle Eastern respiratory syndrome coronavirus: American Mink (Neovision vision), a novel in vivo model of MERS-CoV infection
por: Naveen, S.K., et al.
Publicado: (2016)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats
por: Miyoshi, Toru, et al.
Publicado: (2014)

Dipeptidyl Peptidase-4 Inhibitor (Vildagliptin) Improves Glycemic Control After Meal Tolerance Test by Suppressing Glucagon Release
por: Okamoto, Aki, et al.
Publicado: (2014)

Personal Education Programme in Sweden
por: Muoi, Nguyen Thi
Publicado: (1999)

Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes
por: Smushkin, Galina, et al.
Publicado: (2009)

The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
por: Chakraborty, Sandeep, et al.
Publicado: (2015)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

RS3PE in Association With Dipeptidyl Peptidase-4 Inhibitor: Report of Two Cases
por: Yamauchi, Keishi, et al.
Publicado: (2012)

Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
por: Trzaskalski, Natasha A, et al.
Publicado: (2020)

Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
por: Narayanan, Niya, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases
por: Pasmatzi, Efi, et al.
Publicado: (2011)

The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease
por: Bittle, Polly A.
Publicado: (2017)

Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
por: Batel-Marques, Francisco, et al.
Publicado: (2019)

A Case of Euglycemic Diabetic Ketoacidosis (DKA), Influenza, and a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
por: Jeong, Su Hyun, et al.
Publicado: (2023)

Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 Diabetes
por: Dalla Man, Chiara, et al.
Publicado: (2009)

Response to Comment on Bress et al. Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care 2017;40:1401–1408
por: Bress, Adam P., et al.
Publicado: (2018)

Reevaluating the Evidence for Blood Pressure Targets in Type 2 Diabetes
por: Lamprea-Montealegre, Julio A., et al.
Publicado: (2018)

IFCC Professional Scientific Exchange Programme (PSEP) Report: Plasma Protein Separation Techniques: Ishmael Kasvosve, Zimbabwe: - Report on Scientific Visit
por: Kasvosve, Ishmael
Publicado: (2000)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials
por: Esposito, Katherine, et al.
Publicado: (2014)

Dipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
por: Yabe, Daisuke, et al.
Publicado: (2012)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog
por: Edgerton, Dale S., et al.
Publicado: (2009)

Genetic Risk of Progression to Type 2 Diabetes and Response to Intensive Lifestyle or Metformin in Prediabetic Women With and Without a History of Gestational Diabetes Mellitus
por: Sullivan, Shannon D., et al.
Publicado: (2014)

The Reality of Type 2 Diabetes Prevention
por: Kahn, Richard, et al.
Publicado: (2014)

Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
por: Garvey, W. Timothy, et al.
Publicado: (2014)

A “Spoonful of Sugar” and the Realities of Diabetes Prevention!
por: Cefalu, William T.
Publicado: (2014)

Prevalence of different states of glucose intolerance in Sri Lankan children and adolescents with obesity and its relation to other comorbidities
por: Ciba, Iris, et al.
Publicado: (2020)

Dietary Sugar and Body Weight: Have We Reached a Crisis in the Epidemic of Obesity and Diabetes?: Health Be Damned! Pour on the Sugar
por: Bray, George A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vmlip2cdrpm6rvie93i28aadm5